<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327402</url>
  </required_header>
  <id_info>
    <org_study_id>SHP465-112</org_study_id>
    <nct_id>NCT03327402</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability
      of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25
      milligram (mg) SHP465
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">October 11, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Time Point (AUC0-t) of Sample Collection of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero Predose to Five Hours Postdose (AUC0-5) of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 predose to 5 hours postdose of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Five Hours to the Last Time Point (AUC5-t) of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Area under the plasma concentration versus time curve from time 5 hours to the time of last quantifiable concentration of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Area under the plasma concentration versus time curve from time of dosing to the last measurable concentration of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (24 Hours) at Steady State (AUCtau) of d- and l-amphetamine in Plasma</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Area under the plasma concentration versus time curve over the dosing interval (24 hours) at steady state of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CL/F) for Extravascular Administration of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Apparent total clearance of the drug from plasma after oral administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) Occurring at the Time of Maximum Observed Concentration Sampled During a Dosing Interval of d- and l-amphetamine in Plasma</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Maximum observed plasma concentration of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Plasma Concentration Ctrough at Steady State of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Trough plasma concentration (pre-dose concentrations collected at steady state) of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Time required for the concentration of the drug to reach half of its original value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) During Dosing Interval of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vss/F) at Steady State of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Apparent volume of distribution at steady state after non-intravenous administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) Associated With the Terminal Slope Following Extravascular Administration</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Volume of distribution associated with the terminal slope following extravascular administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Rate Constant (Lambda z) of d- and l-amphetamine</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>First-order elimination rate constant associated with the terminal phase of elimination of d- and l-amphetamine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Weeks 1 up to Week 5</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Any clinically significant deviations from baseline values which are deemed clinically significant in the opinion of the investigator are to be recorded as an AE. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Signs Reported as an Adverse Event</measure>
    <time_frame>Baseline up to Week 5</time_frame>
    <description>Vital signs include blood pressure, pulse, respiratory rate, and body temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as an Adverse Event</measure>
    <time_frame>Baseline up to Week 5</time_frame>
    <description>12-lead ECG will be performed. Any clinically significant change in ECG assessment will be reported as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Height</measure>
    <time_frame>Baseline up to Week 4</time_frame>
    <description>Height (in centimeters or inches) will be measured using a stadiometer with the participant standing on a flat surface without shoes and with the chin parallel to the floor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Weight</measure>
    <time_frame>Baseline up to Week 4</time_frame>
    <description>Weight (in kilograms or pounds) will be measured using a calibrated scale. Participant should be in light clothes and without shoes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Clinical Laboratory Results Reported as an Adverse Event</measure>
    <time_frame>Baseline up to Week 5</time_frame>
    <description>Clinical laboratory (biochemistry, hematology and urinalysis) results out-of-range will be assessed and if they are clinically significant will be reported as AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post Sleep Questionnaire (PSQ)</measure>
    <time_frame>Baseline up to Week 4</time_frame>
    <description>PSQ is a 7-item questionnaire that collects data on average time to sleep, sleep latency, frequency of interrupted sleep, duration of interrupted sleep, total sleep time and sleep quality over the last week. The assessment is done by the nature of the responses, not by a numbered scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>Baseline up to Week 4</time_frame>
    <description>CSHQ screens for the most common sleep problems. CSHQ consists of 33 items within 8 different subscales: bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia-suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline up to Week 4</time_frame>
    <description>C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The assessment is done by the nature of the responses, not by a numbered scale.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>SHP465</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP465</intervention_name>
    <description>SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.</description>
    <arm_group_label>SHP465</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 4-5 years inclusive at the time of consent with a primary
             diagnosis of ADHD (any subtype) based on a detailed psychiatric evaluation using the
             Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
             and has undergone nonpharmacological treatment or has a severe enough condition to
             consider enrollment without undergoing prior nonpharmacological treatment, based on
             the investigator's judgment or has never taken ADHD medication or has taken ADHD
             medication with unacceptable efficacy and/or tolerability.

          2. Participant's parent/legally authorized representative (LAR) must sign the informed
             consent form, and there must be documentation of assent (if applicable) and is willing
             and able to fully comply with all of the testing and requirements defined in the
             protocol.

          3. Participant during the screening period:

             i. Has a total score of ADHD-RS-5 &gt;=28 for boys and &gt;=24 for girls. ii. Has a Clinical
             Global Impressions-Severity of Illness (CGI-S) score &gt;=4. iii.Functions at an
             age-appropriate level intellectually, as determined by the investigator.

          4. Participant has the ability to take investigational product by either swallowing the
             capsule whole or sprinkling the capsule contents in applesauce and ingesting the
             entire mixture immediately without chewing.

          5. Participant has lived with the same parent/LAR for at least 6 months.

        Exclusion Criteria:

          1. Prior enrollment or participation in the study.

          2. Documented allergy, hypersensitivity, or intolerance to amphetamine or to any
             excipients in the investigational product.

          3. Participant cannot swallow a pill and/or applesauce, or has an allergy to applesauce.

          4. Participant is currently taking or has taken ADHD medication with acceptable efficacy
             and tolerability.

          5. Participant has taken ADHD medication within 7 days prior to the administration of
             investigational product.

          6. Participant has used any medication (including over-the-counter, herbal, or
             homeopathic preparations) within 30 days prior to the administration of
             investigational product or 5 half-lives, whichever is longer, with the exception of
             the following:

             i. Thyroid medication ii. Intermittent use of nonsteroidal anti-inflammatory drugs or
             acetaminophen iii. As needed use of a beta-agonists inhaler for mild asthma or
             exercise induced bronchospasm iv. Over-the-counter nonsedating antihistamines for
             allergies. v. Participant has continuously used oral corticosteroids &gt;=7 days in 3
             months prior to investigational product dosing. If continuous use was less than (&lt;) 7
             days, 1 month of washout prior to dosing of investigational product is required.

          7. Within 30 days prior to the administration of investigational product (IP):

             i. Participant has used an IP.

               1. If the elimination half-life of the previous study's IP was less than 6 days,
                  then the last dose of the previous IP should be 30 days prior to the first dose
                  of SHP465.

               2. If the elimination half-life of the previous study's IP was greater than 6 days,
                  then the last dose of the previous IP should be 5 half-lives prior to the dose of
                  SHP465.

          8. Glaucoma.

          9. Known family history of sudden cardiac death or ventricular arrhythmia.

         10. Known history of symptomatic cardiovascular disease, structural cardiac abnormality,
             cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac
             conditions placing them at increased vulnerability to the sympathomimetic effects of a
             stimulant drug.

         11. Any clinically significant ECG or clinically significant laboratory abnormalities at
             the first screening visit based on the investigator's judgment. A single retest of
             laboratory parameters is allowed based on the investigator's judgment.

         12. Marfan's syndrome.

         13. Blood pressure &gt;= 95th percentile for age, sex, and height at the screening visit.

         14. Height and weight &lt;= 5th percentile for age and sex at the first screening visit.

         15. Current abnormal thyroid function test results, defined as abnormal
             thyroid-stimulating hormone, thyroxine (T4), and tri-iodothyronine (T3) at the first
             screening visit. Treatment with a stable dose of thyroid medication for at least 3
             months is permitted.

         16. History of seizures (other than infantile febrile seizures).

         17. Current, controlled (requiring medication or therapy) or uncontrolled, comorbid
             psychiatric disorder including but not limited to any of the following comorbid Axis I
             disorders and Axis II disorders.

         18. Currently considered a suicide risk in the opinion of the investigator, has previously
             made a suicide attempt, or has a prior history of or is currently demonstrating active
             suicidal ideation.

         19. History of physical, sexual, or emotional abuse.

         20. Primary sleep disorder (eg, sleep apnea, narcolepsy).

         21. Eating disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Preferred Research Partners</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Professional Psychiatric Services (PPS)</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHP465</keyword>
  <keyword>ADHD</keyword>
  <keyword>Hyperactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

